Carcinoid Tumor Market Research Report, Site (Lung, Gastrointestinal), Diagnosis (Serology, Imaging, Biopsy), Treatment (Chemotherapy, Radiotherapy), End Users (Hospital & Clinics, Academic Institutes, Research Organization) - Global Forecast Till 2030

Carcinoid Tumor Market Overview

The Carcinoid Tumor Market is projected to reach USD 2,448.1 Million by 2030 at 10.5% CAGR during the forecast period 2022-2030.A neuroendocrine tumor is a form of carcinoid tumor. A neuroendocrine tumor, which is made up of cells that are a mix of hormone-producing endocrine cells and nerve cells, is a neuroendocrine tumor. The GI (gastrointestinal) tract and the lungs are the most prevalent sites for carcinoid tumors. The pancreas, testicles, and ovaries are some of the additional places where carcinoid tumors can form. According to the American Society of Clinical Oncology (ASCO), 8,000 people in the United States were diagnosed with a carcinoid tumor in their gastrointestinal system in 2016.

Intended Audience

• Pharmaceutical companies


• Biotechnological institutes


• Government and Private Laboratories


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Market Research and Consulting Service Providers 

Figure 1:- carcinoid tumor market share, by region

Sources: WHO, annual reports, press release, white paper, and company presentation

Segmentation

The  carcinoid tumor market is segmented on the basis of site, diagnosis, treatment, and end users.

On the basis of site, the Carcinoid Tumor Market is segmented into gastrointestinal, lung, and others. Furthermore, the gastrointestinal segment is sub-segmented into rectum, small intestine, appendix, and others. The lung segmented is sub-segmented into typical, atypical, and others.

On the basis of diagnosis, the market is segmented into serology, imaging, biopsy, and others. The serology segment is sub-segmented into blood test, urine test, molecular test, and others. The imaging segment is sub-segmented into X-ray, CT scan, PET scan, and others.

On the basis of treatment, the market is segmented into surgery, chemotherapy, radiotherapy, and others. The surgery segment is sub-segmented into local excision, radiofrequency ablation (RFA), and others.

On the basis of end users, the market is segmented into hospitals & clinics, academic institutes, research organization, and others

Regional Analysis

America dominates the carcinoid tumor market owing to a well-developed healthcare sector and huge patient population. Apart from this, increasing healthcare expenditure and presence of developed economies within the region are adding fuel to the growth of the market in America.

Europe is the second leading region in the carcinoid tumor market, which is followed by Asia Pacific. Availability of funds for research, huge patient population and government support for research & development are projected to drive the market. According to the National Health Service in 2015, each year about 1,200 people diagnose with carcinoid tumor in the UK.

Asia Pacific is the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies like India and China, and the presence of huge opportunity in the market. Moreover, there are huge opportunities within the region for the growth of the untapped market.

On the other hand, the Middle East & Africa accounts the least share of the carcinoid tumor market due to presence of poor economy, especially, in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.

Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation Recent Developers

Amgen's objective is to serve patients, which includes ensuring that all of our medications satisfy our high-quality standards and are delivered consistently to patients all around the world. Amgen invests in its manufacturing capabilities on a regular basis in order to maintain our industry-leading capabilities and expand our worldwide reach.

Boehringer Ingelheim is a pharmaceutical company based in Germany. The mission of the research-driven pharmaceutical business, Boehringer Ingelheim, is to improve patients' health and quality of life. Boehringer Ingelheim has been a family-owned business since 1885 and is one of the top 20 pharmaceutical businesses in the world. Every day, 50,000 workers in the three business areas of human medicine, animal health, and biopharmaceuticals generate value via innovation. Boehringer Ingelheim's net sales in 2017 were roughly 18.1 billion euros. R & D spending was more than three billion euros or 17.0 percent of net sales.

Key Players in the Carcinoid Tumor Market

Some of the key players in the carcinoid tumor market are Novartis AG (Europe), Amgen Inc. (U.S.), Boehringer Ingelheim GmbH (Europe), AVEO Pharmaceuticals, Inc. (U.S.), Chiasma, Inc. (U.S.), Aegis Therapeutics, LLC (U.S.), CRINETICS PHARMACEUTICALS (U.S.), Delcath Systems Inc. (U.S.), Exelixis, Inc. (U.S.), and others.